09:00 - 10:00 Session 3: Genomics in MPN, MDS, AML
Chair: A Mead (United Kingdom)
- Driver mutations associated with MDS and MPN; any commonality?
F Solé (Spain)
- Genetics of AML and MDS; how different?
E Papaemmanuil (United States)
- Panel discussion
All speakers
10:00 - 11:15 Session 4: HSC Niche
Chair: D Bonnet (United Kingdom)
- The HSC niche in aging
H Geiger (Germany)
- HSCs under inflammatory stress
M Essers (Germany)
- Dissecting niche dependencies during leukaemogenesis
D Bonnet (United Kingdom)
- Panel discussion
All speakers
11:15 - 11:45 Coffee break
11:45 - 13:00 Session 5: Immunome in MPN, MDS and AML
Chair: A Van de Loosdrecht (The Netherlands)
- Immunome for patient stratification; lessons from solid tumours
A Hayday (United Kingdom)
- Inflammation in MPN, MDS and AML; a driving force?
M Raaijmakers (The Netherlands)
- Cellular Immune response in MPN, MDS and AML; Cause or Consequence?
S Kordasti (United Kingdom)
- Panel discussion
All speakers
13:00 - 14:30 Lunch break
13:30 - 14:30 Satellite Symposium 2
14:30 - 15:45 Session 6: Development of biomarkers of disease progression
Chair: K Döhner (Germany)
- AML MRD in 2023
J Cloos (The Netherlands)
- Clonal Evolution and the development of Myeloid Malignancies
J Jansen (The Netherlands)
- Allele burden and prognosis in MPN
A Mead (United Kingdom)
- Panel discussion
All speakers
15:45 - 16:15 Coffee break
16:15 - 17:15 Session 7: Translating Omics to diagnostic tests
- Building prognostic and predictive models using big data
K Porkka (Finland)
- Genomics for patients' stratification in MPN
A Mead (United Kingdom)
- Panel discussion
All speakers
17:15 - 17:45 Debate: Cytometry versus Morphology, time to move on?
Chair: S Kordasti (United Kingdom)
- Pro: A Van de Loosdrecht (The Netherlands)
- Con: Speaker TBC
18:00 - 19:00 Satellite Symposium 3
Back